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Abstract: Multifunctional liposomes containing manganese ferrite/gold core/shell nanoparticles 
were developed. These magnetic/plasmonic nanoparticles were covered by a lipid bilayer or 
entrapped in liposomes, which form solid or aqueous magnetoliposomes as nanocarriers for 
simultaneous chemotherapy and phototherapy. The core/shell nanoparticles were characterized by 
UV/Visible absorption, X-Ray Diffraction (XRD), Transmission Electron Microscopy (TEM), and 
Superconducting Quantum Interference Device (SQUID). The magnetoliposomes were 
characterized by Dynamic Light Scattering (DLS) and TEM. Fluorescence-based techniques (FRET, 
steady-state emission, and anisotropy) investigated the incorporation of a potential anti-tumor 
drug (a thienopyridine derivative) in these nanosystems. The core/shell nanoparticles exhibit sizes 
of 25 ± 2 nm (from TEM), a plasmonic absorption band (λmax = 550 nm), and keep magnetic 
character. XRD measurements allowed for the estimation of 13.3 nm diameter for manganese ferrite 
core and 11.7 nm due to the gold shell. Aqueous magnetoliposomes, with hydrodynamic diameters 
of 152 ± 18 nm, interact with model membranes by fusion and are able to transport the anti-tumor 
compound in the lipid membrane, with a high encapsulation efficiency (EE (%) = 98.4 ± 0.8). Solid 
magnetoliposomes exhibit hydrodynamic diameters around 140 nm and also carry successfully the 
anticancer drug (with EE (%) = 91.2 ± 5.2), while also being promising as agents for phototherapy. 
The developed multifunctional liposomes can be promising as therapeutic agents for combined 
chemo/phototherapy. 
Keywords: magnetic/plasmonic nanoparticles; multifunctional liposomes; manganese ferrite; gold 
shell; anti-tumor drugs; cancer therapy 
 
1. Introduction 
In recent years, a revolution in cancer therapy has taken place due to the development of 
multi-tasked nanostructures or materials for applications in oncology [1,2]. In chemotherapy, the 
ideal nano-encapsulation system should have biophysical properties that favor the passive 
accumulation in tumors upon intravenous administration, as well as controlled triggered release of 
the encapsulated active molecules. In this context, magnetic nano-encapsulation systems are 
promising since they can enable the magnetic drug targeting by static gradient magnetic fields and 
magnetic hyperthermia, which produce local heat as a trigger for drug release and a synergistic 
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cytotoxic effect in cancer cells [3–7]. Additionally, systems based on superparamagnetic 
nanoparticles can generate high-resolution images by T2-weighted magnetic resonance imaging 
(MRI) for tumor diagnosis [7–9].  
Noble metal (Ag, Au) nanoparticles strongly absorb light in the visible region due to coherent 
oscillations of the metal conduction band electrons in strong resonance with visible frequencies of 
light. This phenomenon is known as surface plasmon resonance (SPR) [10–13] and is highly 
dependent on nanoparticles size, shape, surface, and dielectric properties of the surrounding 
medium [14–16]. Light absorbed by nanoparticles is readily dissipated as heat. Due to their large 
absorption cross sections, plasmonic nanoparticles can generate a significant amount of heat and 
increase temperatures in their vicinities [17]. If a sufficient number of nanoparticles are present, the 
temperature fields overlap and create a substantial global temperature rise [18]. From the point of 
view of cancer therapeutics, noble metal nanoparticles become very useful as agents for plasmonic 
photothermal therapy (PTT) on account of their enhanced absorption cross sections, which are four 
to five orders of magnitude larger than those offered by conventional photo-absorbing dyes [16]. 
This strong absorption ensures effective laser therapy at relatively lower energies, which render the 
therapy method minimally invasive. Additionally, metal nanostructures have a higher 
photo-stability and do not suffer from photo-bleaching [16,19]. Recently, plasmonic nanoparticles 
have also been used as photoacoustic imaging (PAI) agents to increase tissue penetration, as well as 
sensitivity and spatial resolution [20]. 
In nanomedicine, systems with combined magnetic and plasmonic properties are of particular 
interest for theranostics since they combine simultaneously multiple imaging modalities for 
diagnosis with complementary synergistic strategies for therapy [21–23]. Gold nanoparticles have 
been largely used in biomedical applications for their low toxicity, great biocompatibility, easy 
conjugation with active biomolecules, and their remarkable optical properties, which enable their 
use as diagnostic and therapeutic agents [19,24]. However, recent works have shown that the 
conjugation of gold nanoparticles with magnetic ones may decrease the overall magnetization of the 
nanostructure [25]. Thus, coating magnetic nanoparticles with gold should be carefully considered 
in order to ensure proper magnetic capabilities for their application. Among all magnetic 
nanoparticles, those of manganese ferrite have recently received great attention for their high 
magnetic susceptibility, which suggests that they may be promising as hyperthermia and magnetic 
drug targeting agents [26,27]. 
In this study, magnetic/plasmonic nanoparticles possessing a manganese ferrite core and a gold 
shell were prepared. In order to develop applications in cancer therapy, the prepared nanoparticles 
were entrapped in liposomes (aqueous magnetoliposomes, AMLs) or covered with a lipid bilayer 
(solid magnetoliposomes, SMLs). These new nanosystems were tested in this scenario as 
nanocarriers for a potential anticancer drug, especially active against melanoma, breast 
adenocarcinoma, and non-small cell lung cancer [28]. In addition, the local heating capability of the 
developed systems was monitored through the fluorescence quenching of rhodamine B 
incorporated in the lipid layer when excited with a light source. Considering their potentialities, the 
new nanosystems developed in this study can be promising for future applications in cancer 
therapy. 
2. Materials and Methods  
All the solutions were prepared using spectroscopic grade solvents and ultrapure water of 
Milli-Q grade (MilliporeSigma, St. Louis, MO, USA).  
2.1. Preparation of Manganese Ferrite/Gold Core/Shell Nanoparticles 
Manganese ferrite nanoparticles (NPs) were synthesized in 5 mL aqueous solution, by the 
co-precipitation method, as previously described [26]. First, an aqueous solution containing 612 μL 
of 50% NaOH solution was heated to 90 °C. Then, a mixture containing 500 μL of 0.5 M MnSO4·H2O 
solution and 500 μL of 1 M FeCl3·6H2O solution was added, drop by drop, to the previously warmed 
basic solution under magnetic stirring. After two hours at 90 °C, manganese ferrite nanoparticles 
 3 of 18 
 
were formed. For purification, the obtained sample was washed several times with ethanol, by 
centrifugation (14,000 g) and magnetic decantation. 
For growth of the gold shell, a method adapted from a previously described procedure was 
used [19]. In addition, 5 mL of an aqueous dispersion of the synthesized MnFe2O4 nanoparticles 
(with concentration of 4 mg/mL) were added to 25 mL of glycerol and heated up to 200 °C, under 
vigorous stirring. Then, 2 mL of 0.02 M solution of gold(III) chloride hydrate (HAuCl4), from 
Sigma-Aldrich (St. Louis, MO, USA), were added dropwise. After 15 minutes under continuous 
stirring at 200 °C, the gold shell was formed around the MnFe2O4 core NPs. To remove glycerol 
residues, the synthesized NPs were washed by centrifugation (14,000 g) with ethanol. 
2.2. Preparation of Magnetoliposomes 
For magnetoliposomes preparation, the lipids L-α-phosphatidylcholine from egg yolk 
(Egg-PC), and 1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DOPG), from 
Sigma-Aldrich (St. Louis, MO, USA), were used in a final concentration of 1 mM. The ethanol 
injection method was employed to obtain aqueous magnetoliposomes (AMLs) [29]. Accordingly, a 
20 mM lipid solution in ethanol was injected, under vigorous vortexing, to an aqueous dispersion of 
manganese ferrite/gold nanoparticles (with 4 mg/mL concentration). After encapsulation, the 
ferrofluid was washed with water and purified by magnetic decantation to remove all the 
non-encapsulated NPs. 
For the preparation of solid magnetoliposomes (SMLs), a method previously described was 
used [30]. First, 10 μL of a solution of the synthesized MnFe2O4/Au core/shell nanoparticles (0.02 
mg/mL) were ultra-sonicated for one minute at 189 W, and 3 mL of chloroform were added to the 
solution. Then, immediately after vigorous agitation, 150 μL of a 20 mM methanolic solution of the 
lipid DOPG (1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt) were injected under 
vortexing to form the first lipid layer of the SMLs. To remove the lipid that was not attached to the 
nanoparticles surface, the particles were washed twice by magnetic decantation with ultrapure 
water. The lipid bilayer was completed by a new injection of 150 μL of 20 mM lipid methanolic 
solution, under vortexing, in 3 mL of aqueous dispersion of the particles with the first lipid layer. 
The SMLs obtained were then washed and purified with ultrapure water by magnetic decantation. 
The anti-tumor compound methyl 3-amino-6-(benzo[d]thiazol-2-ylamino)thieno[3,2-b]pyridine- 
-2-carboxylate was incorporated into aqueous magnetoliposomes by the co-injection method 
(simultaneous injection of compound and lipid) in a final compound concentration of 2 μM. In solid 
magnetoliposomes, the compound was incorporated by injection of an ethanolic solution (0.2 mM) 
immediately before the formation of the second lipid layer. 
2.3. Preparation of Giant Unilamellar Vesicles (GUVs) 
GUVs of soybean lecithin (L-α-phosphatidylcholine from soybean), from Sigma-Aldrich (St. 
Louis, MO, USA), were obtained by the thin film hydration method [31,32]. For that, a lipid film of 
100 μL of soybean lecithin solution (1 mM) was obtained by solvent evaporation under an argon 
stream, and 40 μL of water were added, followed by incubation at 45 °C for 30 minutes. Then, 3 mL 
of glucose aqueous solution (0.1 M) were added and the resulting solution was again incubated at 37 
°C for 2 hours. After incubation, the GUVs suspension was centrifuged at 14,000 g for 30 minutes at 
20 °C, to remove multi-lamellar vesicles and lipid aggregates. 
2.4. Spectroscopic Measurements 
2.4.1. General Methods  
Absorption spectra were performed in a Shimadzu UV-3600 Plus UV-vis-NIR (Shimadzu 
Corporation, Kyoto, Japan) spectrophotometer. Fluorescence measurements were recorded using a 
Horiba Fluorolog 3 spectrofluorimeter (HORIBA Jobin Yvon IBH Ltd., Glasgow, UK), equipped with 
double mono-chromators in both excitation and emission, Glan-Thompson polarizers, and a 
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temperature controlled cuvette holder. Fluorescence spectra were corrected for the instrumental 
response of the system.  
2.4.2. FRET Measurements 
Förster Resonance Energy Transfer (FRET) assays were employed to confirm the formation of 
the lipid bilayer in the solid magnetoliposomes (SMLs). For that purpose, the nitrobenzoxazole 
labeled lipid NBD-C6-HPC (1-palmitoyl-2-{6-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]hexanoyl} 
-sn-glycero-3-phosphocholine) (from Avanti Polar Lipids, Alabaster, AL, USA) was included in the 
first lipid layer, while the rhodamine B labeled lipid Rhodamine B-DHPE 
(1,2-dipalmitoyl-sn-glycero-3-phospho-ethanolamine-N-lissamine rhodamine B sulfonyl 
(ammonium salt)) (from Avanti Polar Lipids, Alabaster, AL, USA) was included in the second lipid 
layer. 
FRET efficiency, ΦRET, defined as the proportion of donor molecules that have transferred their 
excess energy to the acceptor molecules, was calculated through donor emission quenching, by 
taking the ratio of the donor integrated fluorescence intensities in the presence of acceptor (FDA) and 
in the absence of acceptor (FD) (Equation 1) [33].  
ΦRET = 1 −   (1)
The distance between the donor and acceptor molecules was determined through the FRET 
efficiency (Equation 2).  
 =   	1 − ΦΦ 
 
 (2)
where R0 is the Förster radius (critical distance), that can be obtained by the spectral overlap, J(λ), 
between the donor emission and the acceptor absorption, according to Equations (3) and (4) (with R0 
in Å, λ in nm, εA(λ) in M−1 cm−1) [33]. 
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where  = 2 3  is the orientational factor assuming random orientation of the dyes, n is the 
refraction index of the medium, ID(λ) is the fluorescence spectrum of the donor normalized so that 
+ % & (!))! = 1, and εA(λ) is the molar absorption coefficient of the acceptor. Φ , the fluorescence 
quantum yield of the donor in the absence of energy transfer, was determined by the standard 
method (Equation 5) [34,35]. 
 = ,-.

,.-- - (5)
where A is the absorbance at the excitation wavelength, F is the integrated emission area, and n is the 
refraction index of the solvents used. Subscripts refer to the reference (r) or donor (D). The 
absorbance at the excitation wavelength was always lower than 0.1 to avoid the inner filter effects. 
The NBD-C6-HPC molecule intercalated in lipid membranes was used as a reference, Φr = 0.32 at 25 
°C, as reported by Invitrogen [36]. 
The hydrophobic dye Nile Red (energy acceptor) was also incorporated in magnetoliposomes 
labelled with NBD-C6-HPC (NBD as energy donor) for monitoring the interaction of 
magnetoliposomes with GUVs by FRET. 
2.4.3. Fluorescence Anisotropy Measurements 
The steady-state fluorescence anisotropy, r, is calculated by the equation below. 
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 = %// − 0%/1%// + 20%/1 (6)
where IVV and IVH are the intensities of the emission spectra obtained with vertical and horizontal 
polarization, respectively (for vertically polarized excitation light), and 0 = %1//%11  is the 
instrument correction factor, where IHV and IHH are the emission intensities obtained with vertical 
and horizontal polarization (for horizontally polarized excitation light). 
2.4.4. Drug Encapsulation Efficiency 
The encapsulation efficiency, EE (%), of the potential anti-tumor drug in magnetoliposomes, 
was determined through fluorescence emission measurements. Therefore, drug loaded 
magnetoliposomes were subjected to centrifugation at 11,000 rpm for 60 min using Amicon Ultra 
centrifugal filter units 100 kDa (Merck Millipore, Darmstadt, Germany). Then, the filtrate 
(containing the non-encapsulated drug) was pipetted out, the water was evaporated, and the same 
amount of ethanol was added. After vigorous agitation, its fluorescence was measured, which 
allowed it to determine the drug concentration using a calibration curve (fluorescence intensity vs. 
concentration) previously obtained in the same solvent. Three independent measurements were 
performed for each system and standard deviations (SD) were calculated. The encapsulation 
efficiency was determined using Equation (7).  
44(%) =  (67689 8:7;6 − 8:7;6 7< 7 =>8?@;986=) >7:?7;))67689 8:7;6 × 100 (7)
2.5. Structural Characterization 
2.5.1. Transmission Electron Microscopy (TEM) 
TEM images of nanoparticles and solid magnetoliposomes were acquired using a Transmission 
Electron Microscope Leica LEO 906E (Leica Microsystems, Wetzlar, Germany) operating at 120 kV, 
at UME (Electron Microscopy Unit), University of Trás-os-Montes and Alto Douro (Vila Real, 
Portugal). For SMLs, a negative staining was employed, using a 2% aqueous solution of ammonium 
molybdate tetrahydrate. In addition, 20 μL of the sample and 20 μL of the staining solution were 
mixed and a drop of the mixture was placed onto a Formvar grid (Agar Scientific Ltd., Essex, UK), 
held by tweezers. After 20 s, almost all the solution was removed with filter paper and left to dry. 
TEM images were processed using ImageJ software (National Institutes of Health (NIH), Bethesda, 
MD, USA) with the addition of a value to all pixels so that a white background resulted, which was 
followed by inversion and enhanced local contrast. Subsequently, the ParticleSizer plugin [37] was 
used and was followed by particle analysis. The area of each particle allowed an estimation of the 
particle diameter. The resulting histogram was fitted to a bimodal Gaussian distribution. 
2.5.2. X-Ray Diffraction (XRD)  
X-Ray Diffraction (XRD) analyses were performed using a conventional Philips PW 1710 (Royal 
Philips, Amsterdam, The Netherlands) diffractometer, operating with CuKα radiation, in a 
Bragg-Brentano configuration. 
2.5.3. Dynamic Light Scattering (DLS) 
The mean diameter and size distribution (polydispersity index) of aqueous and solid 
magnetoliposomes (1 mM lipid concentration) were measured using Dynamic Light Scattering 
(DLS) equipment NANO ZS Malvern Zetasizer (Malvern Panalytical Ltd., Malvern, UK) at 25 °C, 
using an He-Ne laser of λ = 632.8 nm and a detector angle of 173°. The measurements were also 
carried out for the magnetoliposomes in a solution of human serum albumin (35 mg/mL) in PBS 
buffer (pH = 7.4). Five independent measurements were performed for each sample. 
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2.6. Magnetic Measurements 
Magnetic measurements of the dry core/shell nanoparticles were performed at room 
temperature in a Superconducting Quantum Interference Device (SQUID) magnetometer Quantum 
Design MPMS5XL (Quantum Design Inc., San Diego, CA, USA) using applied magnetic fields up to 
5.5 T. 
2.7. Measurement of the Photothermal Effect 
Solid magnetoliposomes incorporating the labelled lipid Rhodamine B-DHPE were irradiated 
and Rhodamine B emission was monitored by a function of time, using the detection system of a 
SPEX Fluorolog 2 spectrofluorimeter (HORIBA Jobin Yvon IBH Ltd., Glasgow, UK). The irradiation 
setup consisted in a Xenon arc lamp (200 W) and an optical fiber, using a Thorlabs FEL0600 
(Thorlabs Inc., Newton, NJ, USA) long pass filter with cut-on wavelength at 600 nm, to ensure the 
excitation of only the gold nanoparticles (not exciting Rhodamine B dye). 
3. Results and Discussion 
3.1. Nanoparticles Characterization 
3.1.1. Absorption Spectra 
Figure 1 displays the UV-Visible absorption spectrum of the synthesized manganese 
ferrite/gold core/shell nanoparticles. The absorption spectra of net gold nanoparticles and net 
manganese ferrite nanoparticles are also shown for comparison.  
 
Figure 1. UV-Visible absorption spectra of aqueous dispersions of manganese ferrite nanoparticles, 
gold nanoparticles, and MnFe2O4/Au core/shell nanoparticles. 
The spectrum of manganese ferrite NPs is typical of an indirect semiconductor, as reported 
earlier [26], while the spectrum of gold nanoparticles obtained by the standard Turkevish method 
[38] reveals a characteristic local surface plasmon resonance (LSPR) band, with a maximum around 
530 nm. In comparison, the absorption spectrum of manganese ferrite/gold core/shell NPs exhibits a 
broader and red shifted plasmon band (maximum at 550 nm). The absorption spectrum of gold 
nanoshells depends on their thickness, as well as on the refraction index of both core and 
surrounding media [39]. Theoretical studies have shown that, for an air filled core of 10 nm size and 
a gold shell of 5 nm in water medium, the resonance peak is expected to occur at 538 nm, while, for a 
10-nm shell, it should appear at 552 nm [40]. The increase of the core refraction index results in a red 
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shift of the plasmon resonance peak [39]. For a 3-nm gold shell thickness on a 10-nm magnetite core, 
a resonance peak at 560 nm was found [41]. 
3.1.2. X-Ray Diffraction (XRD) Measurements 
XRD analysis confirmed the synthesis of a pure crystalline phase of manganese ferrite/gold 
nanoparticles, since all their characteristic peaks (CIF 2300618 for manganese ferrite and CIF 9013035 
for gold), marked by their indices, were observed (Figure 2b). The percentage amounts obtained for 
MnFe2O4 and Au were 59.1% and 40.9%, respectively. Mean sizes of 13.3 nm for manganese ferrite 
and 11.7 nm for gold, were estimated through a Rietveld analysis using Fullprof software [42]. Table 
1 summarizes the main results of the Rietveld analysis. For the net manganese ferrite powdered 
sample, it resulted in a poor RF factor of 9.0. It was possible to improve it by optimizing the overall 
isothermal factor, Bover, but an unreasonable value of −2.79 was obtained. A similar improvement 
was possible by accounting for the effect of sample microstructure (Figure 2a), according to Equation 
(8) [43], which gives the micro-absorption correction term, P.  
B = B + C sin  G1 −

sin H (8)
where P0 is the bulk contribution to the micro-absorption effect and τ is the normalized surface 
roughness parameter [43]. 
Considering I9 ̅ = 0.01 (μ is the linear absorption coefficient and 9 ̅ is the mean chord length of 
the powder particle) and the values in Table 1 for Equation (8) parameters, a degree of inversion of i 
= 0.60 is obtained for manganese ferrite. This value is close to the one reported by Chen et al. (i = 0.67) 
[44], using a similar preparation method for MnFe2O4. The Rietveld analysis of gold phase was not 
optimal, as the intensity of peak (1 1 1) is lower and that of peak (2 0 0) is higher than the 
experimental ones. In addition, the analysis of MnFe2O4 phase decreased its quality, as the RF factor 
increased from 3.18 to 4.70 and the peak (3 1 1) got much lower than the experimental one. This 
could be due to the expected shell morphology of gold in the prepared MnFe2O4/Au nanocomposites 
in which a layer of gold grows on the MnFe2O4 surface. This morphology, through lattice mismatch 
induced stress, is predictable to change the intensity of the diffraction peaks [45]. An atomistic 
modelling of the core/shell nanoparticle is anticipated to yield a better description of the XRD 
diffractogram [46] and this will be addressed in a future study. The obtained weight fraction of gold 
was 40.9%, but this is calculated using proportionality factors between diffraction intensity and 
mass, ATZs [42], that do not take into account the dependence of diffraction intensity on particle 
size. Since the lattice constant of Au is less than half that of MnFe2O4, the reduction of diffraction 
intensity with particle size is much more pronounced for Au than for MnFe2O4. This means that the 
value given by Fullprof software is expected to be much lower than the real one. Considering the 
obtained size of manganese ferrite of 13.3 nm and using the phase densities that resulted from the 
XRD analysis (5.04 g cm−3 for MnFe2O4 and 19.4 g cm−3 for Au), the mass percentage of gold would be 
98.7% if the obtained size of gold phase (11.7 nm) corresponds to the shell thickness. This percentage 
would change to 95.6% if the obtained size value of 11.7 nm corresponds to the double of the shell 
thickness. This would be true if the effect of the two gold layers in given X-ray crosses contributes 
equally to the broadening of the diffraction peak. Thus, from XRD data analysis, the thickness of the 
gold shell is expected to be 5.85 nm. This value is compatible with the observed position of the 
surface plasmon resonance peak, as discussed in the previous section. Additionally, in 
magnetite/gold core/shell nanoparticles, reported in Reference [41], the diffraction peak widths were 
identical for the 10 nm magnetite core and for the 2 nm gold shell (where its dimensions were 
obtained from HR-TEM measurements). Therefore, the actual value of the gold shell thickness in 
MnFe2O4/Au NPs could be even lower. 
A nanostructure consisting of a 5.85 nm gold shell surrounding a cluster of MnFe2O4 
nanoparticles cannot be ruled out. In that case, the calculated mass percentage of gold changes to 
91% for a compact over-coating layer of 12 spheres. Nevertheless, in the case of gold shell growth, 
the magnetic nanoparticles are dispersed in glycerol at a high temperature, before the addition of 
HAuCl4 solution. This means the magnetic nanoparticles can effectively be dispersed with their 
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surface well stabilized and passivated by the abundant OH groups of glycerol. Furthermore, the 
formation of the gold shell occurs through oxidation of glycerol. This process originates in other 
molecules, such as glyceric acid or tartronic acid, which can act as gold surface stabilizers. This is the 
case in terms of the citric acid in the Turkevish gold nanoparticles synthesis procedure [38]. 
Therefore, the prepared MnFe2O4/Au core/shell nanoparticles are expected to be surface passivated 
by hydroxyacids and, as such, well dispersible in aqueous media. 
 
Figure 2. XRD diffractogram of manganese ferrite (a) and manganese ferrite/gold core/shell 
nanoparticles (b). Gold diffraction peaks are marked by a filled triangle. 
Table 1. Selected Rietveld analysis parameters. 
Sample Ox,y,z (*) i (*) 
Micro 
Absorption 
Correction 
Overall 
Temperature 
Factor, Bover 
Lattice Constant 
(nm) 
Size 
(nm) 
Rf χ2 
MnFe2O4 0.251 0.928 No 0 (+) 0.84693 13.8 9.03 1.33 
MnFe2O4 0.251 0.898 No −2.79 0.84684 13.2 4.45 1.18 
MnFe2O4 0.257 0.60 Yes (#) 0 (+) 0.84685 13.3 3.18 1.18 
MnFe2O4/Au 
0.257 (+) 0.60 (+) 
Yes (##) 
0 (+) 0.84685 (+) 13.3 4.70 
1.56 
--- --- 0 (+) 0.406945 11.7 0.68 
(#) P0 = 0.629, C = 1.31, τ = 0.055. (##) P0 = 0.607, C = 1.15, τ = 0.084. (+) fixed values. (*) Values in CIF 
file 2360018 are Ox,y,z = 0.25053 and i = 0.33. 
3.1.3. Transmission Electron Microscopy (TEM) 
TEM images (Figure 3a) of the MnFe2O4/Au prepared nanoparticles and the corresponding 
image after processing by ImageJ (Figure 3b) revealed a generally spherical shape with the presence 
of some aggregation. These aggregates probably arise from the sample preparation on TEM grids 
(slow evaporation of a drop of an aqueous dispersion of nanoparticles). The size histogram that 
results from the area of the highlighted particles was fitted to a bimodal Gaussian distribution in 
order to better separate the presence of aggregates from the individual nanoparticles (Figure 3c). A 
bimodal size distribution of 25 ± 2 nm and 32 ± 6 nm was obtained. The former population is in 
accordance with the size estimated from XRD measurements, which is 25 nm when the gold shell 
thickness is 5.85 nm. 
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(a) (b) (c) 
Figure 3. (a) TEM image of the synthesized MnFe2O4/Au core/shell nanoparticles. (b) TEM image 
processed by ImageJ (same scale of image a). (c) Particles size histogram and fitting to a bimodal 
Gaussian distribution (total number of 141 particles). 
Below is a critical diameter of 42.9 nm. MnFe2O4 nanoparticles possess a superparamagnetic 
behavior [47,48], losing at least 90% of the magnetization when an applied magnetic field is 
removed, which is important for biomedical applications. The size of the nanoparticles obtained in 
this study is within this limit, and, therefore, these NPs are suitable for applications in biomedicine. 
3.2. Magnetic Properties  
The magnetic properties of MnFe2O4/Au core/shell nanoparticles (Figure 4) were characterized 
by measuring their magnetic hysteresis loop, which shows the relationship between the induced 
magnetic moment and the applied magnetic field (H). The core/shell nanoparticles present a 
superparamagnetic behavior since the ratio between remnant magnetization (Mr) and saturation 
magnetization (Ms) is below 0.1 [49] (Table 2). 
 
Figure 4. Magnetization hysteresis loop of MnFe2O4/Au core/shell nanoparticles measured at room 
temperature. Inset: Enlargement of the loop in the low field region. 
Table 2. Coercive field (Hc), saturation magnetization (Ms), remnant magnetization (Mr), and ratio 
Mr/Ms for MnFe2O4/Au core/shell nanoparticles at room temperature. 
 Hc (Oe) Ms (emu/g) Mr (emu/g) Mr/Ms 
MnFe2O4/Au NPs 13.57 3.15 0.08 0.03 
The low saturation magnetization values are due to the presence of a diamagnetic gold layer. 
The gold shell thickness of MnFe2O4/Au core/shell nanoparticles was estimated using the magnetic 
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hysteresis cycle. The particles were considered to have a well ordered MnFe2O4 core covered by a 
non-magnetic gold shell (with a thickness δ), acting as a “dead layer”. Thus, the obtained saturation 
magnetization, Ms, is proportional to the core volume that possesses a spontaneous magnetization, 
which is related to the thickness of the dead layer and to the particle diameter, through Equation (9) 
[49]. 
KL =  KL M1 − 6OP Q (9)
where D is the particle diameter and Ms0 is the saturation magnetization of MnFe2O4. 
Chen et al. [44] observed that the saturation magnetization of manganese ferrite depends on 
particle size, which is estimated to be a value of 58 emu/g for MnFe2O4 nanoparticles of 13.3 nm (also 
prepared by coprecipitation). Using this value, a gold layer thickness of δ = 4.0 nm is obtained for 
particles with a diameter of 25 nm (from TEM) and Ms = 3.15 emu/g. This is roughly in accordance 
with XRD results. 
3.3. Magnetoliposomes as Drug Nanocarriers 
The obtained magnetic/plasmonic nanoparticles were either entrapped in liposomes (aqueous 
magnetoliposomes, AMLs) or covered by a lipid bilayer that forms the so-called solid 
magnetoliposomes (SMLs). The potential of both types of magnetoliposomes as drug carriers was 
investigated. A potential anti-tumor compound, which is a fluorescent thienopyridine derivative 
(Figure 5), was incorporated into AMLs and SMLs and its fluorescence emission was studied. This 
compound can be promising as an anticancer agent in oncological therapy, as it exhibited very low 
growth inhibitory concentrations (GI50), between 3.5 μM (for A375-C5 melanoma cell line) and 
6.4 μM (for non-small cell lung cancer, NCI-H460 cell line), when tested in vitro in several human 
tumor cell lines [28]. Moreover, the same compound has shown a very low affinity for the 
multi-drug resistance protein (MDR1), which is a protein that promotes drug resistance in cells [50]. 
This compound exhibits fluorescence in several polar and non-polar media, but not in aqueous 
solution [50]. Therefore, fluorescence-based methodologies (fluorescence emission, FRET, and 
fluorescence anisotropy) are advantageous techniques to monitor behavior and location of this 
compound in magnetoliposomes. 
N
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Figure 5. Structure of the potential anti-tumor thienopyridine derivative. 
3.3.1. Aqueous Magnetoliposomes 
The emission of the thienopyridine derivative in AMLs and liposomes (the latter without 
nanoparticles and with the same concentration of compound) is shown in Figure 6(a). Since this 
potential drug is not fluorescent in aqueous media [50], the emission observed is indicative of the 
encapsulation of the compound in magnetoliposomes. A quenching of the compound fluorescence is 
observed in AMLs relative to the liposomes, which confirms its incorporation in the magnetic 
nanocarriers since this effect is attributed to the presence of the nanoparticles that absorb in a wide 
wavelength range [26]. Figure 6(b) displays the absorption spectra of AMLs containing the core/shell 
nanoparticles, with and without the anti-tumor drug, which confirms the successful loading of the 
drug into the magnetoliposomes and shows the overlap of the absorption spectra of nanoparticles 
with the compound fluorescence emission. This indicates that the nanoparticles can quench, by 
energy transfer, the compound fluorescence, as already observed [26]. Additionally, the gold shell 
can also introduce a quenching effect through electron transfer processes. 
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Moreover, the fluorescence anisotropy measurements (Table 3) confirmed that the anti-tumor 
compound is located mainly in the lipid bilayer. The anisotropy values were analogous to those 
previously determined in liposomes of the same lipids [50]. The behavior observed is similar to the 
one previously reported for magnetoliposomes containing manganese ferrite nanoparticles (without 
the gold shell) [26], which indicates that gold does not influence compound location in 
magnetoliposomes. 
  
(a) (b) 
Figure 6. (a) Fluorescence spectra (λexc = 360 nm) of the anti-tumor compound (2 × 10−6 M) in 
liposomes and AMLs of Egg-PC containing MnFe2O4/Au core/shell nanoparticles. (b) Absorption 
spectra of AMLs containing the core/shell nanoparticles with and without the anti-tumor drug. 
The size of DOPG AMLs containing the magnetic/plasmonic nanoparticles were determined by 
Dynamic Light Scattering (DLS), which exhibit hydrodynamic diameters of 152 ± 18 nm and with a 
low polydispersity index (PDI = 0.19 ± 0.04). This size is larger than the one reported for Egg-PC 
aqueous magnetoliposomes containing manganese ferrite nanoparticles [26], but very similar to the 
one of DOPG solid magnetoliposomes based on MnFe2O4 [26]. In the presence of human serum 
albumin (HSA), 35 mg/mL (typical concentration in serum) in PBS buffer, the size of AMLs slightly 
increases and possesses hydrodynamic diameters of 157 ± 29 nm with a slightly higher 
polydispersity (PDI = 0.23 ± 0.09). For enhanced permeability and a retention (EPR) effect of loaded 
drugs, the diameter of (magneto)liposomes must be small. A successful extravasation into tumors 
has been shown to occur for nanocarriers with sizes below 200 nm [51]. Moreover, an encapsulation 
efficiency of EE (%) = 98.4 ± 0.8 was obtained for the anti-tumor thienopyridine derivative in these 
aqueous magnetoliposomes, which anticipate that these systems contain MnFe2O4/Au NPs as very 
promising nanocarriers for anti-cancer drugs.  
Table 3. Steady-state fluorescence anisotropy (r) values, at 25 °C, for the anti-tumor compound in 
magnetoliposomes in comparison with the values in neat liposomes. 
 Lipid r 
Liposomes [50] 
Egg-PC 0.176 
DOPG 0.181 
AMLs 
Egg-PC 0.173 
DOPG 0.168 
SMLs DOPG 0.175 
The interaction of AMLs containing MnFe2O4/Au nanoparticles with Giant Unilamellar 
Vesicles (GUVs), used as models of biological membranes, was also investigated. The aim of 
this study was to evaluate the ability of magnetoliposomes to release drugs by fusing with 
cell membranes, considering future applications in cancer therapy/theranostics. Taking into 
account the fluorescence quenching caused by the presence of the core/shell nanoparticles, 
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the emission of the anti-tumor compound incorporated in aqueous magnetoliposomes was 
measured before and after interaction with GUVs (Figure 7a). After interaction with GUVs, 
the observed unquenching effect indicates the occurrence of membrane fusion between 
AMLs and the model membranes, with an increase in the distance between the drug and the 
nanoparticles (decreasing the interaction that leads to emission quenching).  
To further confirm that this unquenching is, in fact, due to fusion between AMLs and 
GUVs, the interaction between these two systems was also monitored by FRET (Förster 
Resonance Energy Transfer). For that purpose, AMLs containing both the labeled lipid 
NBD-C6-HPC and the lipid probe Nile Red [52–54] were prepared. In this case, the NBD moiety 
acted as the energy donor and the dye Nile Red acted as the energy acceptor [55]. Exciting only the 
donor NBD, a strong band due to Nile Red emission was observed (with maximum around 630 
nm), which resulted from energy transfer to Nile Red (Figure 7b). After interaction with GUVs, the 
donor fluorescence (λmax = 535 nm) increased and the acceptor emission band decreased, which 
showed the diminution of FRET process efficiency and, consequently, proved the membrane fusion 
between AMLs and GUVs. 
  
(a) (b) 
Figure 7. (a) Fluorescence spectra (λexc = 360 nm) of the thienopyridine derivative (2 × 10−6 M) 
in AMLs of Egg-PC containing MnFe2O4/Au nanoparticles, before and after interaction with 
GUVs. (b) Fluorescence spectra (λexc = 400 nm) of AMLs containing both NBD-C6-HPC (2 × 
10−6 M) and Nile Red (2 × 10−6 M), before and after interaction with GUVs. 
3.2.2. Solid Magnetoliposomes 
The preparation of solid magnetoliposomes, where a cluster of nanoparticles is 
successively covered by two lipid layers, was performed using a methodology previously 
developed [30]. This method has proven to be successful for solid magnetoliposomes 
containing magnetic nanoparticles of manganese ferrite [26], nickel ferrite [30], and 
magnetite [56]. To confirm that the same procedure can be applied to nanoparticles with a 
gold shell, the formation of the lipid bilayer around MnFe2O4/Au nanoparticles was 
confirmed by FRET. 
The labeled lipid NBD-C6-HPC (NBD as energy donor) was included in the first lipid 
layer of the SMLs and the lipid Rhodamine B-DHPE (rhodamine as the acceptor) was 
included in the second lipid layer. The emission of SMLs containing only the NBD-labelled 
lipid and SMLs containing both donor and acceptor labeled lipids were measured (Figure 
8a), exciting only the donor NBD. 
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Figure 8. (a) Fluorescence spectra (λexc = 470 nm, no rhodamine excitation) of SMLs of DOPG 
containing MnFe2O4/Au core/shell nanoparticles labeled with only NBD-C6-HPC and labeled 
with both NBD-C6-HPC and rhodamine B-DHPE. (b) TEM image (dark field mode) of SMLs 
containing core/shell nanoparticles (obtained with a negative staining). 
The fluorescence spectrum of SMLs with only the donor shows, as expected, a 
characteristic NBD emission band (λmax = 535 nm). On the other hand, the fluorescence 
spectrum of the SMLs containing both donor and acceptor rates reveals a decrease in the 
NDB emission opposing the strong rise in the rhodamine B emission band, which shows the 
energy transfer of the excited NBD moiety to rhodamine B. A distance between donor and 
acceptor of rDA = 3.1 nm was determined, from the calculated FRET efficiency of 0.65 
(equations 2–5). Considering that donor and acceptor are each in one of the lipid layers, the 
distance between them proves the bilayer formation in SMLs, considering the typical cell 
membrane thickness (7–9 nm) [57]. TEM images of solid magnetoliposomes (Figure 8b) 
containing the core/shell nanoparticles point to nanosystems with diameters around 100 nm. 
DLS measurements revealed that these solid liposomes exhibit hydrodynamic diameters of 
138 ± 19 nm and a low value for the polydispersity index (PDI = 0.20 ± 0.07). In the presence of 
HSA (PBS buffer, pH = 7.4), the size determined by DLS rises to 160 ± 32 nm (PDI = 0.24 ± 
0.08), but is still below 200 nm. 
The incorporation of the anti-tumor thienopyridine derivative in SMLs and the fusion 
with model membranes (GUVs) were confirmed in a similar way to the AMLs. As such, the 
emission of compounds loaded in SMLs was measured, as well as the emission after 
interaction of the SMLs with GUVs (Figure 9a). It was observed that a quenching effect of the 
compound fluorescence emission by the presence of magnetic/plasmonic nanoparticles 
(relative to the observed in liposomes) indicates incorporation of the thienopyridine 
derivative in the SMLs membrane. This quenching is more pronounced than for AMLs due to 
the lower distance between the NPs cluster and the drug. Figure 9(b) shows the absorption 
spectra of drug loaded and unloaded SMLs. Like in the case of AMLs, SMLs can also absorb 
(through the core/shell nanoparticles) in the compound emission region. 
The fluorescence anisotropy value of the anti-tumor drug in these SMLs is also similar to 
the one in liposomes and AMLs of the same lipid (Table 3). This indicates that the main 
location of the compound is in the lipid membrane, as reported for liposomes [50]. The drug 
encapsulation efficiency in SMLs is slightly lower than the one for AMLs, EE (%) = 91.2 ± 5.2, 
but still quite high. 
The unquenching effect detected upon interaction with GUVs proves membrane fusion 
of SMLs with the model membranes. Again, these results are similar to the ones in 
magnetoliposomes containing net MnFe2O4 nanoparticles [26] and, hence, the SMLs 
containing magnetic/plasmonic nanoparticles are promising nanocarriers for this anti-tumor 
drug. 
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Figure 9. (a) Fluorescence spectra (λexc = 360 nm) of the thienopyridine derivative (2 × 10−6 M), 
in SMLs of DOPG containing MnFe2O4/Au core/shell nanoparticles, before and after 
interaction with GUVs. (b) Absorption spectra of SMLs containing the core/shell 
nanoparticles, with and without the anti-tumor drug. 
3.4. Magnetoliposomes as Agents for Phototherapy  
For the study of photo thermal ability, solid magnetoliposomes containing MnFe2O4/Au 
core/shell nanoparticles and including the labeled lipid Rhodamine B-DHPE were synthesized and 
Rhodamine B emission was measured under irradiation (λ > 600 nm) along time (Figure 10). The 
local heating produced by gold propagates by heat diffusion, resulting in quenching of the 
rhodamine emission, due to the increase of efficiency of the non-radiative decay pathways. This 
effect is observed in Figure 10, where a monotonic decrease in Rhodamine fluorescence intensity is 
detected along the irradiation time, which leads to a local temperature increase. The solution 
temperature raised only 2 °C during irradiation time, but this increase also occurred in the absence 
of irradiation. This indicates that the excitation light from the spectrofluorometer, which is always 
incident in the sample during measurement, has higher intensity than the irradiation light (at λ > 600 
nm), so that the effect of the latter is negligible. When only the excitation light hits the sample, the 
rhodamine emission intensity is approximately constant (Figure 10). On the contrary, upon 
irradiation at λ > 600 nm, an emission quenching occurs, that can only originate from a local 
temperature increase. The corresponding heat must, therefore, originate from the photo-thermal 
effect of the gold nanoshell upon light irradiation with λ > 600 nm. Huang et al. [58] studied local 
heating produced by laser irradiation of gold nanoparticles in the interior of a cell, both 
experimentally and theoretically. It was found that, for a 50 mW laser power focused into a 0.1 mm 
spot, the temperature at the vicinity of gold nanoparticles would increase from 25 °C to 
approximately 38 °C, after 4 minutes of irradiation and for an absorption at the plasmon resonance 
wavelength of 0.1. Using a light power meter (Thorlabs PM100USB with a S140C sensor), the light 
intensity through the λ > 600 nm filter was ~5 mW. Assuming 50% loss upon the used coupling to an 
optical fiber with a 1-mm diameter, and considering the final irradiation time of 120 min, the 
equivalent light power in the conditions of the calculations of Huang et al. [58] would be ~18 mW. 
According to the reported linear relation between the calculated temperature near gold 
nanoparticles and irradiation time [58], a local temperature increase of ~5 °C is expected. This 
temperature increase is compatible with the observed rhodamine fluorescence quenching. A much 
higher local temperature increase using laser irradiation of the developed magnetic/plasmonic lipid 
covered systems is then expected. 
Therefore, these results show that solid magnetoliposomes based on manganese ferrite/gold 
core/shell nanoparticles are promising agents for plasmonic photothermal therapy. The local 
temperature increase caused by irradiation of the core/shell nanoparticles will also promote an 
increase in fluidity of the lipid membrane of liposomes, which enhances drug release. 
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Figure 10. Fluorescence intensity (normalized to initial intensity) of irradiated SMLs with 
MnFe2O4/Au core/shell nanoparticles labelled with Rhodamine B-DHPE, as a function of 
time. For comparison, the behavior without irradiation light is also shown. 
4. Conclusions 
In this work, liposomes containing magnetic/plasmonic nanoparticles with manganese ferrite 
core and a gold shell were prepared. The multifunctional liposomes obtained, with sizes around or 
below 150 nm, were revealed to be suitable nanocarriers for an anticancer drug (a thienopyridine 
derivative), exhibiting high encapsulation efficiencies. Drug-loaded aqueous magnetoliposomes 
(with the nanoparticles entrapped in liposomes) were able to interact with model membranes by 
fusion. The solid magnetoliposomes (where the core/shell nanoparticles are covered by a lipid 
bilayer) have shown the ability to be used in photothermia applications. Therefore, the 
multifunctional liposomes containing MnFe2O4/Au core/shell nanoparticles were found to be 
promising agents for combined chemo/phototherapy. 
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